In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Allergan: Not Just a Pretty Face

Executive Summary

Moving from an ophthalmic company with lackluster earnings selling both devices and drugs for the eye, four years ago, Allergan brought in a new CEO to turn around the company. To profit from higher margin businesses, he has refocused Allergan as a specialty pharmaceutical company. Allergan hopes to profit from advantages that its peers in specialty pharmaceuticals don't possess; a great deal of cash generated by Botox, (already a $400 million product), a top-rated sales force, and an internal R&D capability that has a history of bringing to market products in-licensed at early stages. Allergan isn't nearly big enough to compare the breadth of its discovery operations or development pipeline to Big Pharma. Management must provide strategic focus to a mid-sized pharmaceutical company working in multiple non-overlapping markets.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts